Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry
Baughn, L.B., Sachs, Z., Noble-Orcutt, K.E. et al.
Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3-4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature.
Baughn, L.B., Sachs, Z., Noble-Orcutt, K.E. et al. "Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry" Leukemia and Lymphoma (2017): 1,931–40